Groesbeck Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Groesbeck Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,997	Closed	-$281K	–	86
2015 Q4	$281K	Sell	1,997 -200	-9%	-$27.7K	0.18%	74
2015 Q3	$292K	Hold	2,197	–	–	0.18%	70
2015 Q2	$387K	Hold	2,197	–	–	0.19%	72
2015 Q1	$380K	Hold	2,197	–	–	0.18%	74
2014 Q4	$360K	Buy	2,197 +100	+5%	+$16.6K	0.18%	75
2014 Q3	$337K	Hold	2,097	–	–	0.16%	73
2014 Q2	$308K	Buy	2,097 +200	+11%	+$27.7K	0.13%	76
2014 Q1	$263K	Buy	+1,897	New	+$286K	0.12%	75

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Groesbeck Investment Management's JAZZ Position: Q1 2016 in Review

Groesbeck Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 1,997 shares — an estimated $281K sold.

Groesbeck Investment Management first reported a position in JAZZ in Q1 2014 and held it in 8 quarters. The position peaked at $387K in Q2 2015. 340 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

Groesbeck Investment Management reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Groesbeck Investment Management sold 1,997 Jazz Pharmaceuticals shares in Q1 2016, an estimated $281K.
Groesbeck Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Groesbeck Investment Management's Jazz Pharmaceuticals position peaked at $387K in Q2 2015.
340 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Groesbeck Investment Management's 13F filing for Q1 2016, filed 13 May 2016.